Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
| Revenue (Most Recent Fiscal Year) | $4.27B |
| Net Income (Most Recent Fiscal Year) | $-356.15M |
| PE Ratio (Current Year Earnings Estimate) | 10.16 |
| PE Ratio (Trailing 12 Months) | 44.40 |
| PEG Ratio (Long Term Growth Estimate) | 0.38 |
| Price to Sales Ratio (Trailing 12 Months) | 2.74 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.68 |
| Pre-Tax Margin (Trailing 12 Months) | -14.71% |
| Net Margin (Trailing 12 Months) | -8.35% |
| Return on Equity (Trailing 12 Months) | 6.87% |
| Return on Assets (Trailing 12 Months) | 2.44% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.67 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.00 |
| Inventory Turnover (Trailing 12 Months) | 1.06 |
| Book Value per Share (Most Recent Fiscal Quarter) | $71.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $5.76 |
| Earnings per Share (Most Recent Fiscal Year) | $4.68 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.97 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 61.56M |
| Free Float | 58.91M |
| Market Capitalization | $11.70B |
| Average Volume (Last 20 Days) | 1.03M |
| Beta (Past 60 Months) | 0.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |